Aflibercept Injection for Proliferative Diabetic Retinopathy

Phase 2 Completed 12 enrolled University of Oklahoma

RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.

Timeline

Start: 2013-03
Primary completion: 2014-02
Completion: 2015-11

Publications

Dervenis P, Dervenis N, Smith JM, Steel DH. Anti-vascular endothelial growth factors in combination with vitrectomy for complications of proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2023 May 31;5(5):CD008214. doi: 10.1002/14651858.CD008214.pub4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Aflibercept	Protein / enzyme biologic	2 mg	Intravitreal

Indications

No indication recorded.